Last updated: 5/12/25
Years published: 2025
NORD gratefully acknowledges Sean Dailey, MS, CGC, Ping-Yee Billie Au, MD, PhD, FRCPC, FCCMG, Clinical Geneticist, Alberta Children’s Hospital, University of Calgary and Antonie D. Kline, MD, FACMG, FAAP, Director of Clinical Genetics, Harvey Institute for Human Genetics, Greater Baltimore Medical Center, for the preparation of this report.
Summary
Au-Kline syndrome is a rare genetic condition associated with intellectual disability, global developmental delay, low muscle tone and other features. As of 2025, there have been more than 75 individuals identified to have Au-Kline syndrome worldwide.1,2
Many people with Au-Kline syndrome have specific facial features such as eyes that look longer or more open, droopy eyelids, shallow eye sockets, a wide nose with a wide bridge, a downturned mouth and a tongue with a deep groove. Other features may include early fusion of the skull bones, heart problems, abnormalities of the roof of the mouth such as cleft palate, swelling or other abnormalities of kidneys, and differences of the genitals and bones. Some people may have problems with automatic body functions such as unusual sweating, problems with digestion, reduced or absent reflexes, a high sensitivity to heat and a high pain tolerance. Feeding difficulties, vision and hearing problems, reduced growth and muscle weakness may also occur.1-3
Au-Kline syndrome is an autosomal dominant condition caused by changes (variants) in one copy of the HNRNPK gene. All affected individuals to date have Au-Kline syndrome because of a random (de novo) variant that was not inherited from a parent.1
The diagnosis is suspected based on signs and symptoms and confirmed with a genetic test. There is currently no cure, but a diagnosis allows for appropriate monitoring and treatment of associated symptoms.1
Au-Kline syndrome can cause a wide range of physical and developmental symptoms. Symptoms of Au-Kline syndrome may start to appear in a newborn and some differences may be identified before birth. These symptoms can vary from person to person but the most common symptoms include:1-3
Many individuals have characteristic facial features that include:1,3
Many individuals have heart problems that are present from birth (congenital heart defects):1,3
Other features include:1-3
Au-Kline syndrome is caused by changes (variants) in a gene called HNRNPK. This gene gives instructions to make a protein called heterogenous nuclear riboprotein K, or hnRNP K. This protein helps control how genetic information is used in the body. It works by attaching to single strands of DNA or RNA and helps other proteins do their jobs, like turning genes on or off and making proteins from RNA. Disease-causing variants in HNRNPK prevent hnRNP K from doing its job, leading to the physical and developmental features seen in Au-Kline syndrome.1,3
Inheritance
Au-Kline syndrome follows autosomal dominant inheritance. Dominant genetic disorders occur when only a single copy of a disease-causing gene variant is necessary to cause the disease. The gene variant can be inherited from either parent or can be the result of a new (de novo) changed gene in the affected individual that is not inherited. The risk of passing the gene variant from an affected parent to a child is 50% for each pregnancy. The risk is the same for males and females. All individuals reported with Au-Kline syndrome whose parents have undergone genetic testing have the condition because of a de novo disease-causing HNRNPK variant.1,2
Au-Kline syndrome is a very rare disorder that was first described in 2015.1,3 It was recognized shortly afterwards that Au-Kline syndrome is the same condition described clinically as Okamoto syndrome in 1997.4 The exact number of affected individuals is currently unknown, but as of 2025, more than 75 individuals have been identified worldwide. Over 40 of these individuals have been written about in medical reports.1
Au-Kline syndrome may be suspected when a young child has global developmental delay and/or intellectual disability, low muscle tone (hypotonia) and at least four of the following six characteristic facial features:1
The diagnosis of Au-Kline syndrome is confirmed with the identification of a disease-causing variant in the HNRNPK gene by genetic testing.1
There is currently no cure for Au-Kline syndrome. Treatment involves managing symptoms through a multidisciplinary approach to improve quality of life, maximize function and reduce complications. Several different specialists may be involved in a patient’s care to address specific symptoms.1,2
A consultation with a developmental pediatrician is recommended to ensure the involvement of appropriate resources and to support parents in maximizing quality of life. Early intervention programs are recommended for access to occupational, physical, speech and feeding therapies.1
Referrals to other specialties may include neurology, neurosurgery, otolaryngology (ENT), cardiology, nephrology, urology, gastroenterology, orthopedics, ophthalmology, audiology and endocrinology to address specific symptoms or concerns.1,2
Genetic counseling is recommended for individuals affected by Au-Kline syndrome and their families. The genetic counselor can provide information about how this condition can be passed down in families, coordinate genetic testing and offer additional resources and support.1,2
Information on current clinical trials is posted on the Internet at https://clinicaltrials.gov/
All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
Email: [email protected]
Some current clinical trials also are posted on the following page on the NORD website: https://rarediseases.org/living-with-a-rare-disease/find-clinical-trials/
For information about clinical trials sponsored by private sources, contact: http://www.centerwatch.com/
For information about clinical trials conducted in Europe, contact: https://www.clinicaltrialsregister.eu/
NORD strives to open new assistance programs as funding allows. If we don’t have a program for you now, please continue to check back with us.
NORD and MedicAlert Foundation have teamed up on a new program to provide protection to rare disease patients in emergency situations.
Learn more https://rarediseases.org/patient-assistance-programs/medicalert-assistance-program/Ensuring that patients and caregivers are armed with the tools they need to live their best lives while managing their rare condition is a vital part of NORD’s mission.
Learn more https://rarediseases.org/patient-assistance-programs/rare-disease-educational-support/This first-of-its-kind assistance program is designed for caregivers of a child or adult diagnosed with a rare disorder.
Learn more https://rarediseases.org/patient-assistance-programs/caregiver-respite/